Results 131 to 140 of about 264,257 (370)

Metabolism‐Regulating Nanomedicines for Cancer Therapy

Advanced NanoBiomed Research, EarlyView.
This review highlights metabolism‐regulating nanomedicines designed to target glycolytic, lipid, amino acid, and nucleotide pathways in tumors. By incorporating metabolism‐regulating agents into versatile nanocarriers such as liposomes, micelles, dendrimers, and engineered bacteria, these platforms achieve targeted delivery, controlled release ...
Xiao Wu, Shiyi Geng, Jian Yang
wiley   +1 more source

Sinonasal diffuse large B-cell lymphoma: own clinical observation and literature review

Онкогематология
Diffuse large B-cell lymphoma is the most common immunomorphological variant of lymphoma in adults. Extranodal lesions are observed in a third of patients at the disease onset.
M. A. Mingalimov, E. A. Baryakh, O. L. Kochneva, E. N. Misyurina, Yu. Yu. Polyakov, E. I. Zhelnova, K. V. Yatskov, A. B. Makeshova, T. N. Tolstykh, T. S. Chudnova, D. D. Ivanova, D. V. Lebedev, E. N. Zotina, D. E. Gagloeva, M. M. Beregov, E. A. Mamatturdiev, I. V. Samsonova, M. A. Lysenko   +17 more
doaj   +1 more source

Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma [PDF]

, 2009
Signaling through the Notch1 receptor has a pivotal role in early thymocyte development. Gain of Notch1 function results in the development of T-cell acute lymphoblastic leukemia in a number of mouse experimental models, and activating Notch1 mutations ...
Chiba Shigeru, Fukayama Masashi, Hangaishi Akira, Izutsu Koji, Kumano Keiki, Kurokawa Mineo, Lee Suk-young, Matsumoto Akihiko, Nakazaki Kumi, Nannya Yasuhito, Ogawa Seishi, Ota Satoshi, Ota Yasunori, Sakata-Yanagimoto Mamiko, Sanada Masashi, Seto Masao, Suzuki Ritsuro, Yagita Hideo, Yamamoto Go, 千葉 滋, 坂田（柳元） 麻実子   +20 more
core   +1 more source

Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.

Journal of Clinical Oncology, 2019
PURPOSE High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH) has a poor outcome after standard chemoimmunotherapy. We sought to understand the biologic underpinnings of HGBL-DH/TH with BCL2 rearrangements (HGBL-DH/TH- BCL2)
Daisuke Ennishi, A. Jiang, M. Boyle, B. Collinge, B. Grande, S. Ben-Neriah, C. Rushton, Jeffrey M. Tang, N. Thomas, G. Slack, P. Farinha, K. Takata, T. Miyata‐Takata, J. Craig, A. Mottok, B. Meissner, Saeed Saberi, Ali Bashashati, D. Villa, K. Savage, L. Sehn, R. Kridel, A. Mungall, M. Marra, Sohrab P. Shah, C. Steidl, J. Connors, R. Gascoyne, Ryan D. Morin, D. Scott   +29 more
semanticscholar   +1 more source

Expert Perspective: Diagnosis and Treatment of Castleman Disease

Arthritis &Rheumatology, EarlyView.
Castleman disease (CD) is a major diagnostic challenge for rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region, whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y. C. Chen, Lu Zhang, David C. Fajgenbaum   +2 more
wiley   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell‐Targeted Therapies

Arthritis &Rheumatology, Accepted Article.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no FDA‐approved disease‐modifying therapies for SjD.
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis [PDF]

, 2017
Jeong Hyeon Lee, Hoiseon Jeong, Jung-Woo Choi, HwaEun Oh, Young-Sik Kim   +4 more
openalex   +1 more source

Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells

Journal of Experimental Medicine, 2001
Gene expression profiling has revealed that diffuse large B cell lymphoma (DLBCL) consists of at least two distinct diseases. Patients with one DLBCL subtype, termed activated B cell–like (ABC) DLBCL, have a distinctly inferior prognosis.
R. Davis, K. Brown, U. Siebenlist, L. Staudt   +3 more
semanticscholar   +1 more source

Machine learning methods for predicting adverse drug events: A systematic review

British Journal of Clinical Pharmacology, EarlyView.
Abstract Predicting adverse drug events (ADEs) in outpatient settings is crucial for improving medication safety, identifying high‐risk patients and reducing health‐care costs. While traditional methods struggle with the complexity of health‐care data, machine learning (ML) models offer improved prediction capabilities; however, their effectiveness in ...
Niaz Chalabianloo, Fatemeh Ahmadi, Mohammad Ali Omrani, Sheikh S. Abdullah, Neda Rostamzadeh, Atefeh Jafari, Lujain Izzedin, Kamran Sedig, Flory T. Muanda   +8 more
wiley   +1 more source

Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies

Journal of Hematology & Oncology
Diffuse large B-cell lymphoma (DLBCL) is an aggressive, yet curable malignancy, that has had practice changing treatment approvals in both the frontline and relapsed setting in the last 5 years. Advent of novel therapeutic options in the recent years has
Allison M. Bock, Narendranath Epperla
doaj   +1 more source